Idarucizumab is the first Food and Drugs Administration (FDA) approved reversal agent for
anticoagulant dabigatran, a direct thrombin inhibitor. Emerging evidence suggests
idarucizumab can improve clinical outcome following dabigatran-associated hemorrhage,
however, its specific use in intracranial hemorrhage has been poorly described. The aim of
this study was to systematically review the available literature of idarucizumab in the setting
of dabigatran-associated ICH to evaluate its efficacy in the stabilizing/resolving of the …